PDS Biotechnology Dirección

Dirección controles de criterios 1/4

El CEO de PDS Biotechnology's es Frank Bedu-Addo , nombrado en Mar 2019, tiene una permanencia de 5.08 años. compensación anual total es $2.30M, compuesta por 23.5% salario y 76.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.88% de las acciones de la empresa, por valor de $2.25M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 5.1 años, respectivamente.

Información clave

Frank Bedu-Addo

Chief Executive Officer (CEO)

US$5.0m

Compensación total

Porcentaje del salario del CEO	11.6%
Permanencia del CEO	5.2yrs
Participación del CEO	1.9%
Permanencia media de la dirección	1.9yrs
Promedio de permanencia en la Junta Directiva	5.2yrs

Actualizaciones recientes de la dirección

Recent updates

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Jan 13

PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101

Feb 03

PDS Biotechnology gives new CFO ~202K stock grant

Jan 06

PDS Biotech launches mid-stage PDS0101 combo trial in head & neck cancer

Nov 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Frank Bedu-Addo en comparación con los beneficios de PDS Biotechnology?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$5m	US$580k	-US$43m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$2m	US$540k	-US$41m
Sep 30 2022	n/a	n/a	-US$28m
Jun 30 2022	n/a	n/a	-US$28m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$7m	US$475k	-US$17m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$815k	US$450k	-US$15m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$3m	US$356k	-US$7m

Compensación vs. Mercado: La compensación total de Frank($USD2.30M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Frank ha aumentado mientras la empresa no es rentable.

CEO

Frank Bedu-Addo (58 yo)

5.2yrs

Permanencia

US$5,011,234

Compensación

Dr. Frank K. Bedu-Addo, Ph D., served as Interim Principal Financial Officer for PDS Biotechnology Corporation since September 30, 2021 until October 2021. He serves as Chief Executive Officer of PDS Biote...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Frank Bedu-Addo	President	5.2yrs	US$5.01m	1.88% $ 2.8m
Gregory Conn	Chief Scientific Officer	5.2yrs	US$1.68m	0.34% $ 496.8k
Lars Boesgaard	Principal Financial & Accounting Officer and CFO	less than a year	sin datos	sin datos
Stephan Toutain	Chief Operating Officer	no data	sin datos	sin datos
Joe Dervan	VP of Research & Development	3.3yrs	sin datos	sin datos
Deanne Randolph	Head of Investor Relations	no data	sin datos	sin datos
Spencer Brown	Senior VP	1.9yrs	sin datos	0% $ 0
Kirk Shepard	Chief Medical Officer	less than a year	sin datos	sin datos
Janetta Trochimiuk	Controller	no data	sin datos	sin datos

1.9yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PDSB no se considera experimentado ( 1.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Frank Bedu-Addo	President	5.2yrs	US$5.01m	1.88% $ 2.8m
Gregory Freitag	Independent Director	5.2yrs	US$105.49k	0.13% $ 185.5k
Richard Sykes	Independent Director	5.2yrs	US$94.49k	1.21% $ 1.8m
Stephen Glover	Independent Chairman	5.1yrs	US$135.99k	0.17% $ 256.4k
Jerold Woodward	Member of Scientific Advisory Board	no data	sin datos	sin datos
Kamil Ali-Jackson	Independent Director	4.3yrs	US$106.49k	0.032% $ 47.3k
Mark Einstein	Member of Scientific Advisory Board	no data	sin datos	sin datos
Darron Brown	Member of Scientific Advisory Board	no data	sin datos	sin datos
Leaf Huang	Member of Scientific Advisory Board	no data	sin datos	sin datos
Samir Khleif	Member of Scientific Advisory Board	no data	sin datos	sin datos
Lisa Rohan	Chair of the Scientific Advisory Board	no data	sin datos	sin datos
Neil Gross	Member of Scientific Advisory Board	no data	sin datos	sin datos

5.2yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de PDSB se considera experimentada (5.1 años de antigüedad promedio).

PDS Biotechnology Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer

PDS Biotechnology Corporation, Annual General Meeting, Jun 24, 2024

PDS Biotechnology Corporation Announces Executive Changes

Pds Biotech Announces CFO Changes

PDS Biotechnology Corporation, Annual General Meeting, Jul 14, 2023

Insufficient new directors

Recent updates

PDS Biotechnology Corporation to Report Q1, 2024 Results on May 15, 2024

PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer

PDS Biotechnology Corporation, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

New minor risk - Shareholder dilution

PDS Biotechnology Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

PDS Biotechnology Corporation Announces Publication of Preclinical Research

PDS Biotechnology Corporation Announces Executive Changes

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Pds Biotech Announces CFO Changes

Price target decreased by 8.4% to US$17.67

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients

PDS Biotechnology Corporation to Report Q3, 2023 Results on Nov 14, 2023

PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO

PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

New major risk - Financial position

PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial

PDS Biotechnology Corporation to Report Q2, 2023 Results on Aug 14, 2023

PDS Biotechnology Corporation to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA in Head and Neck Cancer Patients at ESMO Congress 2023

PDS Biotechnology Corporation Strengthens Intellectual Property Portfolio Governing A Combination of Versamune®? and PDS0301

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the Versatile-002 Trial Evaluating Pds0101 and Keytruda in Head and Neck Cancer

PDS Biotechnology Corporation, Annual General Meeting, Jul 14, 2023

PDS Biotechnology Corporation Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with Keytruda (Pembrolizumab) for Head and Neck Cancer Patients

Pds Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of Versatile-002 Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

PDS Biotechnology Corporation to Report Q1, 2023 Results on May 15, 2023

Insufficient new directors

Price target increased by 7.9% to US$19.43

PDS Biotechnology Corporation Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune

PDS Biotechnology Corporation Announces Preclinical Studies Involving Infectimune

PDS Biotechnology Corporation Announces Abstract Accepted for Presentation At ESMO Targeted Anticancer Therapies Congress

PDS Biotechnology Corporation Reports Median Overall Survival of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 Months

Price target increased to US$18.25

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

President exercised options and sold US$562k worth of stock

Price target increased to US$18.00

PDS Biotechnology Corporation Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from Immunocerv Phase 2 Clinical Trial

PDS Biotechnology Corporation Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

PDS Biotechnology Corporation to Report Q3, 2022 Results on Nov 14, 2022

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

PDS Biotechnology Corporation Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

Price target decreased to US$17.71

PDS Biotechnology Corporation Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA(R)

PDS Biotech jumps 13% as FDA clears further development of lead asset

PDS Biotechnology Corporation Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers

PDS Biotechnology files for $150 mixed shelf offering

PDS Biotech Independent Data Monitoring Committee Recommends Versatile-002 Trial Continuation Without Modifications

PDS Biotech spikes as panel backs continuation of cancer trial for lead asset

PDS Biotechnology Corporation to Report Q2, 2022 Results on Aug 08, 2022

PDS Biotechnology Corporation Announces Presentation of Universal Flu Vaccine Preclinical Data At American Society of Virology Meeting

PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business

PDS Biotechnology Corporation Appoints Spencer Brown as Senior Vice President, General Counsel

U.S. Food and Drug Administration Grants PDS Biotechnology Fast Track Designation for Lead Candidate Pds0101

PDS Biotechnology Corporation Announces Expansion of Its VERSATILE-002 Clinical Trial into Europe

PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data

PDS Biotechnology Corporation Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer At Asco 2022

PDS Biotechnology Corporation Appoints Sanjay Zaveri as Senior Vice President, Business Development

PDS Biotechnology Corporation, Annual General Meeting, Jun 15, 2022

PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Price target increased to US$20.50

No longer forecast to breakeven

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers

PDS Biotechnology Corporation Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

PDS Biotechnology Corporation Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

Forecast to breakeven in 2024

Price target increased to US$20.50